<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7033156/results/search/disease/results.xml">
  <result pre="10.1038/s41598-020-59476-4 : Article An electronic alert system increases screening for" exact="hepatitis" post="B and C and improves management of patients with"/>
  <result pre="visit http://creativecommons.org/licenses/by/4.0/. Abstract Treatment of haematological disorders in patients with" exact="chronic hepatitis" post="B or resolved infection (anti-HBc-positive) is associated with a"/>
  <result pre="http://creativecommons.org/licenses/by/4.0/. Abstract Treatment of haematological disorders in patients with chronic" exact="hepatitis" post="B or resolved infection (anti-HBc-positive) is associated with a"/>
  <result pre="haematological disorders in patients with chronic hepatitis B or resolved" exact="infection" post="(anti-HBc-positive) is associated with a risk of hepatitis B"/>
  <result pre="or resolved infection (anti-HBc-positive) is associated with a risk of" exact="hepatitis" post="B reactivation. Moreover, patients with chronic hepatitis C have"/>
  <result pre="with a risk of hepatitis B reactivation. Moreover, patients with" exact="chronic hepatitis" post="C have a higher risk of haematological malignancies than"/>
  <result pre="a risk of hepatitis B reactivation. Moreover, patients with chronic" exact="hepatitis" post="C have a higher risk of haematological malignancies than"/>
  <result pre="An electronic alert system was developed to promote screening of" exact="hepatitis" post="B (HBV) and C (HCV) in patients starting haematological"/>
  <result pre="HBsAg in 2 patients. Overall, 68% of patients with any" exact="viral hepatitis" post="markers were previously not know, and the impact was"/>
  <result pre="in 2 patients. Overall, 68% of patients with any viral" exact="hepatitis" post="markers were previously not know, and the impact was"/>
  <result pre="the alert system. In summary, an electronic alert system increased" exact="viral hepatitis" post="screening in patients receiving haematological treatment and led to"/>
  <result pre="alert system. In summary, an electronic alert system increased viral" exact="hepatitis" post="screening in patients receiving haematological treatment and led to"/>
  <result pre="management of these patients, including avoided HBV reactivation. Subject terms" exact="Hepatitis" post="B Hepatitis C Funding https://doi.org/10.13039/100005564Gilead Sciences (Gilead) GoSHAPE European"/>
  <result pre="these patients, including avoided HBV reactivation. Subject terms Hepatitis B" exact="Hepatitis" post="C Funding https://doi.org/10.13039/100005564Gilead Sciences (Gilead) GoSHAPE European programme grantRiveiro-BarcielaMar"/>
  <result pre="C Funding https://doi.org/10.13039/100005564Gilead Sciences (Gilead) GoSHAPE European programme grantRiveiro-BarcielaMar Introduction" exact="Viral infection" post="by hepatitis B and C plays an important role"/>
  <result pre="Funding https://doi.org/10.13039/100005564Gilead Sciences (Gilead) GoSHAPE European programme grantRiveiro-BarcielaMar Introduction Viral" exact="infection" post="by hepatitis B and C plays an important role"/>
  <result pre="Sciences (Gilead) GoSHAPE European programme grantRiveiro-BarcielaMar Introduction Viral infection by" exact="hepatitis" post="B and C plays an important role in patients"/>
  <result pre="an important role in patients with haematological malignancies. Individuals with" exact="chronic hepatitis" post="B virus (HBV) infection, (i.e., HBsAg-positive), and even those"/>
  <result pre="important role in patients with haematological malignancies. Individuals with chronic" exact="hepatitis" post="B virus (HBV) infection, (i.e., HBsAg-positive), and even those"/>
  <result pre="virus (HBV) infection, (i.e., HBsAg-positive), and even those with resolved" exact="infection" post="(HBsAg-negative/anti-HBc-positive) are at risk of HBV reactivation when receiving"/>
  <result pre="ranging from asymptomatic HBV DNA elevation to the development of" exact="acute" post="liver failure with an extremely high mortality rate3, which"/>
  <result pre="from asymptomatic HBV DNA elevation to the development of acute" exact="liver failure" post="with an extremely high mortality rate3, which results in"/>
  <result pre="benefit from HBV prophylaxis5. However, the rate of testing for" exact="viral hepatitis" post="in the haematological population is relatively low. The reported"/>
  <result pre="from HBV prophylaxis5. However, the rate of testing for viral" exact="hepatitis" post="in the haematological population is relatively low. The reported"/>
  <result pre="with haematological malignancies in a large study in a US" exact="cancer" post="centre was as low as 66% over a 7-year"/>
  <result pre="94% and anti-HBc screening from 30% to 85%7. As to" exact="hepatitis" post="C virus (HCV) infection, there is a well-established association"/>
  <result pre="risk 60% higher in HCV-infected individuals than in uninfected controls8." exact="Diffuse large B-cell lymphoma" post="(DLBCL), lymphoplasmacytic lymphoma and marginal zone lymphoma are the"/>
  <result pre="higher in HCV-infected individuals than in uninfected controls8. Diffuse large" exact="B-cell lymphoma" post="(DLBCL), lymphoplasmacytic lymphoma and marginal zone lymphoma are the"/>
  <result pre="in HCV-infected individuals than in uninfected controls8. Diffuse large B-cell" exact="lymphoma" post="(DLBCL), lymphoplasmacytic lymphoma and marginal zone lymphoma are the"/>
  <result pre="individuals than in uninfected controls8. Diffuse large B-cell lymphoma (DLBCL)," exact="lymphoplasmacytic lymphoma" post="and marginal zone lymphoma are the most commonly linked"/>
  <result pre="than in uninfected controls8. Diffuse large B-cell lymphoma (DLBCL), lymphoplasmacytic" exact="lymphoma" post="and marginal zone lymphoma are the most commonly linked"/>
  <result pre="uninfected controls8. Diffuse large B-cell lymphoma (DLBCL), lymphoplasmacytic lymphoma and" exact="marginal zone lymphoma" post="are the most commonly linked malignancies9. In view of"/>
  <result pre="Diffuse large B-cell lymphoma (DLBCL), lymphoplasmacytic lymphoma and marginal zone" exact="lymphoma" post="are the most commonly linked malignancies9. In view of"/>
  <result pre="and most were Caucasian. The most common malignancies were DLBCL," exact="multiple myeloma" post="and follicular lymphoma. Four (1%) patients were anti-HIV-positive and"/>
  <result pre="most were Caucasian. The most common malignancies were DLBCL, multiple" exact="myeloma" post="and follicular lymphoma. Four (1%) patients were anti-HIV-positive and"/>
  <result pre="Caucasian. The most common malignancies were DLBCL, multiple myeloma and" exact="follicular lymphoma." post="Four (1%) patients were anti-HIV-positive and 18 (4.3%) reported"/>
  <result pre="(1%) patients were anti-HIV-positive and 18 (4.3%) reported previously known" exact="viral hepatitis." post="Table 1 Baseline characteristics of patients undergoing chemotherapy for"/>
  <result pre="n(%) Caucasian 398 (94.8%) Asian 10 (2.4%) Hispanic 8 (1.9%)" exact="African" post="4 (1%) Age, mean ± SD 63 ± 16 Most common hematological malignancy,"/>
  <result pre="8 (1.9%) African 4 (1%) Age, mean ± SD 63 ± 16 Most common" exact="hematological malignancy," post="n(%) Diffuse large B cell lymphoma 72 (17.1%) Multiple"/>
  <result pre="4 (1%) Age, mean ± SD 63 ± 16 Most common hematological malignancy, n(%)" exact="Diffuse" post="large B cell lymphoma 72 (17.1%) Multiple mieloma 65"/>
  <result pre="63 ± 16 Most common hematological malignancy, n(%) Diffuse large B cell" exact="lymphoma" post="72 (17.1%) Multiple mieloma 65 (15.5%) Follicular lymphoma 57"/>
  <result pre="hematological malignancy, n(%) Diffuse large B cell lymphoma 72 (17.1%)" exact="Multiple" post="mieloma 65 (15.5%) Follicular lymphoma 57 (13.6%) Acute leukemia"/>
  <result pre="large B cell lymphoma 72 (17.1%) Multiple mieloma 65 (15.5%)" exact="Follicular lymphoma" post="57 (13.6%) Acute leukemia 41 (9.8%) Chronic myeloid leukemia"/>
  <result pre="B cell lymphoma 72 (17.1%) Multiple mieloma 65 (15.5%) Follicular" exact="lymphoma" post="57 (13.6%) Acute leukemia 41 (9.8%) Chronic myeloid leukemia"/>
  <result pre="72 (17.1%) Multiple mieloma 65 (15.5%) Follicular lymphoma 57 (13.6%)" exact="Acute" post="leukemia 41 (9.8%) Chronic myeloid leukemia 37 (8.8%) Hodgkin"/>
  <result pre="(17.1%) Multiple mieloma 65 (15.5%) Follicular lymphoma 57 (13.6%) Acute" exact="leukemia" post="41 (9.8%) Chronic myeloid leukemia 37 (8.8%) Hodgkin lymphoma"/>
  <result pre="65 (15.5%) Follicular lymphoma 57 (13.6%) Acute leukemia 41 (9.8%)" exact="Chronic" post="myeloid leukemia 37 (8.8%) Hodgkin lymphoma 22 (5.2%) Myelodysplastic"/>
  <result pre="(15.5%) Follicular lymphoma 57 (13.6%) Acute leukemia 41 (9.8%) Chronic" exact="myeloid leukemia" post="37 (8.8%) Hodgkin lymphoma 22 (5.2%) Myelodysplastic syndrome 22"/>
  <result pre="Follicular lymphoma 57 (13.6%) Acute leukemia 41 (9.8%) Chronic myeloid" exact="leukemia" post="37 (8.8%) Hodgkin lymphoma 22 (5.2%) Myelodysplastic syndrome 22"/>
  <result pre="(13.6%) Acute leukemia 41 (9.8%) Chronic myeloid leukemia 37 (8.8%)" exact="Hodgkin lymphoma" post="22 (5.2%) Myelodysplastic syndrome 22 (5.2%) Chronic lymphocytic leukemia"/>
  <result pre="Acute leukemia 41 (9.8%) Chronic myeloid leukemia 37 (8.8%) Hodgkin" exact="lymphoma" post="22 (5.2%) Myelodysplastic syndrome 22 (5.2%) Chronic lymphocytic leukemia"/>
  <result pre="(9.8%) Chronic myeloid leukemia 37 (8.8%) Hodgkin lymphoma 22 (5.2%)" exact="Myelodysplastic syndrome" post="22 (5.2%) Chronic lymphocytic leukemia 18 (4.3%) Anti-CD20-containing regimens,"/>
  <result pre="Chronic myeloid leukemia 37 (8.8%) Hodgkin lymphoma 22 (5.2%) Myelodysplastic" exact="syndrome" post="22 (5.2%) Chronic lymphocytic leukemia 18 (4.3%) Anti-CD20-containing regimens,"/>
  <result pre="37 (8.8%) Hodgkin lymphoma 22 (5.2%) Myelodysplastic syndrome 22 (5.2%)" exact="Chronic" post="lymphocytic leukemia 18 (4.3%) Anti-CD20-containing regimens, n(%) 166 (39.5%)"/>
  <result pre="(8.8%) Hodgkin lymphoma 22 (5.2%) Myelodysplastic syndrome 22 (5.2%) Chronic" exact="lymphocytic leukemia" post="18 (4.3%) Anti-CD20-containing regimens, n(%) 166 (39.5%) Tyrosine-kinase inhibitors,"/>
  <result pre="Hodgkin lymphoma 22 (5.2%) Myelodysplastic syndrome 22 (5.2%) Chronic lymphocytic" exact="leukemia" post="18 (4.3%) Anti-CD20-containing regimens, n(%) 166 (39.5%) Tyrosine-kinase inhibitors,"/>
  <result pre="Anti-CD20-containing regimens, n(%) 166 (39.5%) Tyrosine-kinase inhibitors, n(%) 64 (15.2%)" exact="HIV infection," post="n(%) 4 (1%) Previously known viral hepatitis, n(%) 18"/>
  <result pre="n(%) 64 (15.2%) HIV infection, n(%) 4 (1%) Previously known" exact="viral hepatitis," post="n(%) 18 (4.3%)* Anti-HCV positive 10 HBsAg positive 1"/>
  <result pre="the variables. Performance of the electronic alert system Impact on" exact="viral hepatitis" post="screening At the first prescription, the serological panel was"/>
  <result pre="variables. Performance of the electronic alert system Impact on viral" exact="hepatitis" post="screening At the first prescription, the serological panel was"/>
  <result pre="receiving anti-CD20-containing regimens (69% vs 55%, p = 0.002) or therapy for" exact="multiple myeloma" post="(69% vs 59%, p = 0.075); a very low rate was"/>
  <result pre="anti-CD20-containing regimens (69% vs 55%, p = 0.002) or therapy for multiple" exact="myeloma" post="(69% vs 59%, p = 0.075); a very low rate was"/>
  <result pre="the highest percentage of completed panels seen in patients with" exact="primary" post="cerebral lymphoma, DLBCL, and Burkitt’s lymphoma (100%, 83.3%, and"/>
  <result pre="highest percentage of completed panels seen in patients with primary" exact="cerebral lymphoma," post="DLBCL, and Burkitt’s lymphoma (100%, 83.3%, and 80%, respectively)"/>
  <result pre="seen in patients with primary cerebral lymphoma, DLBCL, and Burkitt’s" exact="lymphoma" post="(100%, 83.3%, and 80%, respectively) and the lowest in"/>
  <result pre="83.3%, and 80%, respectively) and the lowest in those with" exact="chronic" post="myeloid leukaemia (CML) (16.2%). Following the alert, 115 additional"/>
  <result pre="80%, respectively) and the lowest in those with chronic myeloid" exact="leukaemia" post="(CML) (16.2%). Following the alert, 115 additional cases were"/>
  <result pre="(16.2%). Following the alert, 115 additional cases were tested for" exact="viral hepatitis," post="increasing the overall screening rate to 87.9% (Fig. 1)."/>
  <result pre="patients is summarized in Table 2. Overall, anti-CD20-containing regimens and" exact="DLBCL" post="patients were the ones with the highest screening rates,"/>
  <result pre="patients CML had the lowest. Mean age of patients with" exact="complete" post="viral panel did not differed to those without (62.8"/>
  <result pre="CML had the lowest. Mean age of patients with complete" exact="viral" post="panel did not differed to those without (62.8 vs"/>
  <result pre="Impact of the electronic alert system (EAS) on screening for" exact="viral hepatitis" post="markers. At the start of new therapies for haematological"/>
  <result pre="of the electronic alert system (EAS) on screening for viral" exact="hepatitis" post="markers. At the start of new therapies for haematological"/>
  <result pre="markers. At the start of new therapies for haematological patients," exact="viral hepatitis" post="markers were tested in 60.5% of the total. Following"/>
  <result pre="At the start of new therapies for haematological patients, viral" exact="hepatitis" post="markers were tested in 60.5% of the total. Following"/>
  <result pre="the screening rate significantly increased to 87.9%. Table 2 Overall" exact="viral hepatitis" post="screening rate according to epidemiological, clinical and therapeutic factors."/>
  <result pre="screening rate significantly increased to 87.9%. Table 2 Overall viral" exact="hepatitis" post="screening rate according to epidemiological, clinical and therapeutic factors."/>
  <result pre="≥65 years 227 88.5% 0.374 Caucasian race 398 87.9% 0.514" exact="DLBCL" post="72 97.2% 0.003 Multiple myeloma 65 93.8% 0.074 Chronic"/>
  <result pre="0.374 Caucasian race 398 87.9% 0.514 DLBCL 72 97.2% 0.003" exact="Multiple" post="myeloma 65 93.8% 0.074 Chronic myeloid leukemia 37 48.6%"/>
  <result pre="Caucasian race 398 87.9% 0.514 DLBCL 72 97.2% 0.003 Multiple" exact="myeloma" post="65 93.8% 0.074 Chronic myeloid leukemia 37 48.6% &amp;lt;0.001"/>
  <result pre="0.514 DLBCL 72 97.2% 0.003 Multiple myeloma 65 93.8% 0.074" exact="Chronic" post="myeloid leukemia 37 48.6% &amp;lt;0.001 Anti-CD20-containing regimens 166 93.4%"/>
  <result pre="DLBCL 72 97.2% 0.003 Multiple myeloma 65 93.8% 0.074 Chronic" exact="myeloid leukemia" post="37 48.6% &amp;lt;0.001 Anti-CD20-containing regimens 166 93.4% 0.003 Tyrosine-kinase"/>
  <result pre="72 97.2% 0.003 Multiple myeloma 65 93.8% 0.074 Chronic myeloid" exact="leukemia" post="37 48.6% &amp;lt;0.001 Anti-CD20-containing regimens 166 93.4% 0.003 Tyrosine-kinase"/>
  <result pre="in contrast with the rest of the cohort. Prevalence of" exact="viral hepatitis" post="markers Anti-HBc alone was detected in 57 patients, anti-HCV"/>
  <result pre="contrast with the rest of the cohort. Prevalence of viral" exact="hepatitis" post="markers Anti-HBc alone was detected in 57 patients, anti-HCV"/>
  <result pre="Therefore, the status of 68% of patients testing positive for" exact="viral hepatitis" post="markers had been unknown previously. Management of patients testing"/>
  <result pre="the status of 68% of patients testing positive for viral" exact="hepatitis" post="markers had been unknown previously. Management of patients testing"/>
  <result pre="antiviral prophylaxis. Among patients receiving tyrosine-kinase inhibitors, the underlying haematological" exact="disease" post="had an impact on the prescription rate of antiviral"/>
  <result pre="chart showing the electronic alert system (EAS) for screening of" exact="viral hepatitis" post="markers in patients undergoing haematological therapy. In collaboration with"/>
  <result pre="showing the electronic alert system (EAS) for screening of viral" exact="hepatitis" post="markers in patients undergoing haematological therapy. In collaboration with"/>
  <result pre="in haematological patients. In patients with positive results or an" exact="absence of" post="data, the EAS automatically sends an e-mail to the"/>
  <result pre="3 preconfigured test requests were created, one for patients with" exact="chronic hepatitis" post="B, one for those with chronic hepatitis C, and"/>
  <result pre="preconfigured test requests were created, one for patients with chronic" exact="hepatitis" post="B, one for those with chronic hepatitis C, and"/>
  <result pre="for patients with chronic hepatitis B, one for those with" exact="chronic hepatitis" post="C, and one for anti-HBc-positive patients and those lacking"/>
  <result pre="patients with chronic hepatitis B, one for those with chronic" exact="hepatitis" post="C, and one for anti-HBc-positive patients and those lacking"/>
  <result pre="and one for anti-HBc-positive patients and those lacking data on" exact="viral hepatitis" post="markers. NA, not available. Figure 3 Use of antiviral"/>
  <result pre="one for anti-HBc-positive patients and those lacking data on viral" exact="hepatitis" post="markers. NA, not available. Figure 3 Use of antiviral"/>
  <result pre="higher in patients treated with anti-CD20-containing regimens and those with" exact="follicular lymphoma," post="and was lower in TKI-treated patients. DLBCL, Diffuse B"/>
  <result pre="with anti-CD20-containing regimens and those with follicular lymphoma, and was" exact="lower" post="in TKI-treated patients. DLBCL, Diffuse B cell lymphoma; CLL/CML,"/>
  <result pre="with follicular lymphoma, and was lower in TKI-treated patients. DLBCL," exact="Diffuse" post="B cell lymphoma; CLL/CML, chronic lymphocytic/myeloid leukaemia; CR, containing"/>
  <result pre="lower in TKI-treated patients. DLBCL, Diffuse B cell lymphoma; CLL/CML," exact="chronic" post="lymphocytic/myeloid leukaemia; CR, containing regimen; TKI, tyrosine-kinase inhibitors. Concerning"/>
  <result pre="patients, the one diagnosed by the EAS had a detectable" exact="viral" post="load (154 IU/mL), and antiviral prophylaxis with nucleos(t)ide analogues"/>
  <result pre="nucleos(t)ide analogues (NUCs) was prescribed. The other patient had HBeAg-negative" exact="chronic hepatitis" post="and was already receiving a NUC, which was maintained."/>
  <result pre="analogues (NUCs) was prescribed. The other patient had HBeAg-negative chronic" exact="hepatitis" post="and was already receiving a NUC, which was maintained."/>
  <result pre="analysed in all cases and 2 patients had a detectable" exact="viral" post="load, one with Burkitt’s lymphoma and the other with"/>
  <result pre="2 patients had a detectable viral load, one with Burkitt’s" exact="lymphoma" post="and the other with follicular lymphoma. These two patients"/>
  <result pre="viral load, one with Burkitt’s lymphoma and the other with" exact="follicular lymphoma." post="These two patients were later treated with direct-acting antiviral"/>
  <result pre="previously. Four (36.4%) were liver-transplant recipients undergoing chemotherapy for post-transplant" exact="lymphoproliferative disease" post="(PTLD). Discussion Implementation of an electronic alert system had"/>
  <result pre="Four (36.4%) were liver-transplant recipients undergoing chemotherapy for post-transplant lymphoproliferative" exact="disease" post="(PTLD). Discussion Implementation of an electronic alert system had"/>
  <result pre="an electronic alert system had a positive impact on the" exact="viral hepatitis" post="screening rate in haematological patients receiving specific therapies, with"/>
  <result pre="electronic alert system had a positive impact on the viral" exact="hepatitis" post="screening rate in haematological patients receiving specific therapies, with"/>
  <result pre="of the EAS lies in the diagnosis of previously unknown" exact="viral hepatitis" post="markers, particularly HBV. In our cohort, 80% of the"/>
  <result pre="the EAS lies in the diagnosis of previously unknown viral" exact="hepatitis" post="markers, particularly HBV. In our cohort, 80% of the"/>
  <result pre="also found to be useful for diagnosing new cases of" exact="chronic hepatitis" post="C, which led to the start of treatment with"/>
  <result pre="found to be useful for diagnosing new cases of chronic" exact="hepatitis" post="C, which led to the start of treatment with"/>
  <result pre="has been extensively studied. The hazard depends on the underlying" exact="disease" post="and therapy scheme, but mainly on HBV status2,14. Hence,"/>
  <result pre="therapy scheme, but mainly on HBV status2,14. Hence, testing for" exact="viral hepatitis" post="markers before starting these drugs is vital to identify"/>
  <result pre="scheme, but mainly on HBV status2,14. Hence, testing for viral" exact="hepatitis" post="markers before starting these drugs is vital to identify"/>
  <result pre="Hepatology Department, which facilitated linkage to care in patients with" exact="chronic hepatitis" post="B or C and the request for viral markers"/>
  <result pre="Department, which facilitated linkage to care in patients with chronic" exact="hepatitis" post="B or C and the request for viral markers"/>
  <result pre="with chronic hepatitis B or C and the request for" exact="viral" post="markers in patients without this data. The results of"/>
  <result pre="this real-world study bring to light the differing perception of" exact="viral hepatitis" post="risk depending on the patient’s therapeutic regimen and underlying"/>
  <result pre="real-world study bring to light the differing perception of viral" exact="hepatitis" post="risk depending on the patient’s therapeutic regimen and underlying"/>
  <result pre="in recent years other chemotherapy schemes, such as those for" exact="multiple myeloma," post="have also been associated with a risk of HBV"/>
  <result pre="patients prescribed anti-CD20-containing regimens received prophylaxis, including all patients with" exact="follicular lymphoma." post="However, our data indicated an alarmingly low concern about"/>
  <result pre="have shown a risk of HBV reactivation, including development of" exact="acute" post="liver failure21,24, only one retrospective study including 10 anti-HBc-positive"/>
  <result pre="a mean follow-up of more than 3 years, despite an" exact="absence of" post="antiviral prophylaxis25. In our cohort, although the concern for"/>
  <result pre="low in the population receiving tyrosine kinase inhibitors (62.5%), the" exact="complete" post="testing data showed 17 anti-HBc-positive individuals. Among these, 12"/>
  <result pre="during the first year of therapy. Regarding the prevalence of" exact="viral hepatitis," post="3.2% of patients tested anti-HCV positive, a value 3"/>
  <result pre="area26. Only 2 of the anti-HCV-positive patients had a detectable" exact="viral" post="load. These findings can be explained by the fact"/>
  <result pre="an electronic alert system had a positive impact on the" exact="viral hepatitis" post="screening rate in patients receiving haematological therapy. This, in"/>
  <result pre="electronic alert system had a positive impact on the viral" exact="hepatitis" post="screening rate in patients receiving haematological therapy. This, in"/>
  <result pre="of these patients, with diagnosis of previously unknown cases of" exact="chronic" post="viral hepatitis and possible avoidance of HBV reactivations. Methods"/>
  <result pre="these patients, with diagnosis of previously unknown cases of chronic" exact="viral hepatitis" post="and possible avoidance of HBV reactivations. Methods Study design"/>
  <result pre="patients, with diagnosis of previously unknown cases of chronic viral" exact="hepatitis" post="and possible avoidance of HBV reactivations. Methods Study design"/>
  <result pre="relevant data, 3 preconfigured blood tests were created: one to" exact="complete" post="the study of HBsAg-positive individuals (Code 520, which included"/>
  <result pre="quantitative HBsAg, HBV DNA, HBeAg, anti-HBe, anti-hepatitis D virus, human" exact="immunodeficiency" post="virus (HIV) serology, and anti-HCV), another for anti-HBc positive"/>
  <result pre="treatment schedule was prescribed, the computerized system requested the patient’s" exact="viral hepatitis" post="status if it had not been previously introduced. If"/>
  <result pre="schedule was prescribed, the computerized system requested the patient’s viral" exact="hepatitis" post="status if it had not been previously introduced. If"/>
  <result pre="had not been previously introduced. If data were lacking and" exact="viral hepatitis" post="screening had not been performed within the first 3"/>
  <result pre="not been previously introduced. If data were lacking and viral" exact="hepatitis" post="screening had not been performed within the first 3"/>
  <result pre="within the first 3 months after the therapy prescription, the" exact="viral hepatitis" post="panel was added to the patient’s next scheduled blood"/>
  <result pre="the first 3 months after the therapy prescription, the viral" exact="hepatitis" post="panel was added to the patient’s next scheduled blood"/>
  <result pre="Department physicians underwent training sessions to highlight the importance of" exact="hepatitis" post="B and C screening, the rationale to set up"/>
  <result pre="EAS according to the following items: Number of patients whose" exact="viral hepatitis" post="status was checked after the EAS warning. All patients"/>
  <result pre="according to the following items: Number of patients whose viral" exact="hepatitis" post="status was checked after the EAS warning. All patients"/>
  <result pre="lacking data at the first prescription were checked for later" exact="viral hepatitis" post="screening requests from the Haematology Department. Number of patients"/>
  <result pre="data at the first prescription were checked for later viral" exact="hepatitis" post="screening requests from the Haematology Department. Number of patients"/>
  <result pre="from the Haematology Department. Number of patients with newly diagnosed" exact="viral hepatitis" post="markers. Number of HBV prophylaxis therapies initiated as a"/>
  <result pre="the Haematology Department. Number of patients with newly diagnosed viral" exact="hepatitis" post="markers. Number of HBV prophylaxis therapies initiated as a"/>
  <result pre="Clinical Practice guidelines, and local regulatory requirements. Since screening of" exact="viral hepatitis" post="markers is considered within recommended daily clinical practice, no"/>
  <result pre="Practice guidelines, and local regulatory requirements. Since screening of viral" exact="hepatitis" post="markers is considered within recommended daily clinical practice, no"/>
  <result pre="date of birth, sex), clinical (malignancy, treatment regimen, previously known" exact="viral hepatitis" post="infection, prior treatment for viral hepatitis, antiviral therapy), and"/>
  <result pre="of birth, sex), clinical (malignancy, treatment regimen, previously known viral" exact="hepatitis" post="infection, prior treatment for viral hepatitis, antiviral therapy), and"/>
  <result pre="treatment regimen, previously known viral hepatitis infection, prior treatment for" exact="viral hepatitis," post="antiviral therapy), and serological (HBsAg, anti-HBc, anti-HCV, and HIV"/>
  <result pre="available) data were recorded, as well as antiviral treatment for" exact="chronic hepatitis" post="C and nucleos(t)ide analogue prophylaxis for HBsAg- or anti-HBc-positive"/>
  <result pre="data were recorded, as well as antiviral treatment for chronic" exact="hepatitis" post="C and nucleos(t)ide analogue prophylaxis for HBsAg- or anti-HBc-positive"/>
  <result pre="for patients referred to the Hepatology Department and those with" exact="chronic hepatitis" post="B, who were treated in all cases. Laboratory measurements"/>
  <result pre="patients referred to the Hepatology Department and those with chronic" exact="hepatitis" post="B, who were treated in all cases. Laboratory measurements"/>
  <result pre="and HCV (anti-HCV) were analysed by commercial enzyme immunoassays. The" exact="lower" post="limit of quantification of anti-HBs was 10 mIU/mL and"/>
  <result pre="limit of quantification of anti-HBs was 10 mIU/mL and the" exact="upper" post="limit, 500 mIU/mL. Serum HBV DNA was quantified by"/>
  <result pre="with a COBAS 6800 HBV test (Roche Diagnostics, Mannheim, Germany):" exact="lower" post="limit of quantification, 20 IU/mL and lower limit of"/>
  <result pre="Diagnostics, Mannheim, Germany): lower limit of quantification, 20 IU/mL and" exact="lower" post="limit of detection, 10 IU/mL. Statistical analysis Normally-distributed quantitative"/>
  <result pre="interquartile range. Categorical variables were compared using the chi-square or" exact="Fisher" post="exact test, as appropriate, and expressed as frequencies and"/>
  <result pre="declare no competing interests. References References 1.HwangJPLokASManagement of patients with" exact="hepatitis" post="B who require immunosuppressive therapyNature reviews. Gastroenterology &amp;amp; hepatology20141120921910.1038/nrgastro.2013.21624247262"/>
  <result pre="reviews. Gastroenterology &amp;amp; hepatology20141120921910.1038/nrgastro.2013.21624247262 2.YeoWet al.Hepatitis B virus reactivation in" exact="lymphoma" post="patients with prior resolved hepatitis B undergoing anticancer therapy"/>
  <result pre="al.Hepatitis B virus reactivation in lymphoma patients with prior resolved" exact="hepatitis" post="B undergoing anticancer therapy with or without rituximabJournal of"/>
  <result pre="or without rituximabJournal of clinical oncology: official journal of the" exact="American" post="Society of Clinical Oncology20092760561110.1200/jco.2008.18.018219075267 3.Lok, A. S. et al."/>
  <result pre="of Clinical Oncology20092760561110.1200/jco.2008.18.018219075267 3.Lok, A. S. et al. Reactivation of" exact="hepatitis" post="B virus replication in patients receiving cytotoxic therapy. Report"/>
  <result pre="a prospective study. Gastroenterology100, 182–188, doi:S0016508591000185 [pii] (1991). 4.HsuCet al.Chemotherapy-induced" exact="hepatitis" post="B reactivation in lymphoma patients with resolved HBV infection:"/>
  <result pre="182–188, doi:S0016508591000185 [pii] (1991). 4.HsuCet al.Chemotherapy-induced hepatitis B reactivation in" exact="lymphoma" post="patients with resolved HBV infection: a prospective studyHepatology (Baltimore,"/>
  <result pre="with resolved HBV infection: a prospective studyHepatology (Baltimore, Md.)2014592092210010.1002/hep.26718 5.PerrilloRPMartinPLokASPreventing" exact="hepatitis" post="B reactivation due to immunosuppressive drug treatmentsJama20153131617161810.1001/jama.2015.257125790287 6.HwangJPet al.Trends"/>
  <result pre="B reactivation due to immunosuppressive drug treatmentsJama20153131617161810.1001/jama.2015.257125790287 6.HwangJPet al.Trends in" exact="hepatitis" post="B virus screening at the onset of chemotherapy in"/>
  <result pre="screening at the onset of chemotherapy in a large US" exact="cancer" post="centerBMC cancer20131353410.1186/1471-2407-13-53424209764 7.SampedroBet al.Computerized physician order entry-based system to"/>
  <result pre="biologic agents: the PRESCRIB projectHepatology (Baltimore, Md.)20146010611310.1002/hep.27103 8.YounossiZParkHHenryLAdeyemiAStepanovaMExtrahepatic Manifestations of" exact="Hepatitis" post="C: A Meta-analysis of Prevalence, Quality of Life, and"/>
  <result pre="know?Therapeutic advances in hematology201679410710.1177/204062071562392427054025 10.PaulSet al.Role of surface antibody in" exact="hepatitis" post="B reactivation in patients with resolved infection and hematologic"/>
  <result pre="surface antibody in hepatitis B reactivation in patients with resolved" exact="infection" post="and hematologic malignancy: A meta-analysisHepatology (Baltimore, Md.)20176637938810.1002/hep.29082 11.HuangYHet al.Randomized"/>
  <result pre="Md.)20176637938810.1002/hep.29082 11.HuangYHet al.Randomized controlled trial of entecavir prophylaxis for rituximab-associated" exact="hepatitis" post="B virus reactivation in patients with lymphoma and resolved"/>
  <result pre="prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with" exact="lymphoma" post="and resolved hepatitis BJournal of clinical oncology: official journal"/>
  <result pre="hepatitis B virus reactivation in patients with lymphoma and resolved" exact="hepatitis" post="BJournal of clinical oncology: official journal of the American"/>
  <result pre="resolved hepatitis BJournal of clinical oncology: official journal of the" exact="American" post="Society of Clinical Oncology2013312765277210.1200/jco.2012.48.593823775967 12.SanagawaAet al.Outcomes of the implementation"/>
  <result pre="implementation of the computer-assisted HBView system for the prevention of" exact="hepatitis" post="B virus reactivation in chemotherapy patients: a retrospective analysisJournal"/>
  <result pre="Drug safety warning—New boxed warning, recommendations to decrease risk of" exact="hepatitis" post="B reactivation. US Food and Drug Administration 2013. 14.YeoWChanHLHepatitis"/>
  <result pre="reactivation associated with anti-neoplastic therapyJ Gastroenterol Hepatol201328313710.1111/j.1440-1746.2012.07280.x23020594 15.KooYXet al.Risk of" exact="hepatitis" post="B virus (HBV) reactivation in hepatitis B surface antigen"/>
  <result pre="Hepatol201328313710.1111/j.1440-1746.2012.07280.x23020594 15.KooYXet al.Risk of hepatitis B virus (HBV) reactivation in" exact="hepatitis" post="B surface antigen negative/hepatitis B core antibody positive patients"/>
  <result pre="antiviral prophylaxisAnnals of hematology2011901219122310.1007/s00277-011-1241-021520001 16.TsukuneYet al.Incidence and clinical background of" exact="hepatitis" post="B virus reactivation in multiple myeloma in novel agents’"/>
  <result pre="al.Incidence and clinical background of hepatitis B virus reactivation in" exact="multiple myeloma" post="in novel agents’ eraAnnals of hematology2016951465147210.1007/s00277-016-2742-727358178 17.TsukuneYet al.Incidence and"/>
  <result pre="and clinical background of hepatitis B virus reactivation in multiple" exact="myeloma" post="in novel agents’ eraAnnals of hematology2016951465147210.1007/s00277-016-2742-727358178 17.TsukuneYet al.Incidence and"/>
  <result pre="agents’ eraAnnals of hematology2016951465147210.1007/s00277-016-2742-727358178 17.TsukuneYet al.Incidence and risk factors of" exact="hepatitis" post="B virus reactivation in patients with multiple myeloma in"/>
  <result pre="risk factors of hepatitis B virus reactivation in patients with" exact="multiple myeloma" post="in an era with novel agents: a nationwide retrospective"/>
  <result pre="factors of hepatitis B virus reactivation in patients with multiple" exact="myeloma" post="in an era with novel agents: a nationwide retrospective"/>
  <result pre="era with novel agents: a nationwide retrospective study in JapanBlood" exact="cancer" post="journal2017763110.1038/s41408-017-0002-229167420 18.PerrilloRPGishRFalck-YtterYTAmerican Gastroenterological Association Institute technical review on prevention"/>
  <result pre="Gastroenterological Association Institute technical review on prevention and treatment of" exact="hepatitis" post="B virus reactivation during immunosuppressive drug therapyGastroenterology2015148221244.e22310.1053/j.gastro.2014.10.03825447852 19.Inayat, F."/>
  <result pre="virus reactivation during immunosuppressive drug therapyGastroenterology2015148221244.e22310.1053/j.gastro.2014.10.03825447852 19.Inayat, F. et al." exact="Hepatitis" post="B virus reactivation following imatinib therapy: A comparative review"/>
  <result pre="Oncology Pharmacy Practitioners, 1078155218790337, 10.1177/1078155218790337 (2018). 20.LaiGMYanSLChangCSTsaiCYHepatitis B reactivation in" exact="chronic" post="myeloid leukemia patients receiving tyrosine kinase inhibitorWorld journal of"/>
  <result pre="Pharmacy Practitioners, 1078155218790337, 10.1177/1078155218790337 (2018). 20.LaiGMYanSLChangCSTsaiCYHepatitis B reactivation in chronic" exact="myeloid leukemia" post="patients receiving tyrosine kinase inhibitorWorld journal of gastroenterology2013191318132110.3748/wjg.v19.i8.131823483799 21.IkedaKet"/>
  <result pre="Practitioners, 1078155218790337, 10.1177/1078155218790337 (2018). 20.LaiGMYanSLChangCSTsaiCYHepatitis B reactivation in chronic myeloid" exact="leukemia" post="patients receiving tyrosine kinase inhibitorWorld journal of gastroenterology2013191318132110.3748/wjg.v19.i8.131823483799 21.IkedaKet"/>
  <result pre="patients receiving tyrosine kinase inhibitorWorld journal of gastroenterology2013191318132110.3748/wjg.v19.i8.131823483799 21.IkedaKet al.Fatal" exact="hepatitis" post="B virus reactivation in a chronic myeloid leukemia patient"/>
  <result pre="of gastroenterology2013191318132110.3748/wjg.v19.i8.131823483799 21.IkedaKet al.Fatal hepatitis B virus reactivation in a" exact="chronic" post="myeloid leukemia patient during imatinib mesylate treatmentLeukemia &amp;amp; lymphoma20064715515710.1080/1463923050023681816321842"/>
  <result pre="gastroenterology2013191318132110.3748/wjg.v19.i8.131823483799 21.IkedaKet al.Fatal hepatitis B virus reactivation in a chronic" exact="myeloid leukemia" post="patient during imatinib mesylate treatmentLeukemia &amp;amp; lymphoma20064715515710.1080/1463923050023681816321842 22.KangBWet al.Chronic"/>
  <result pre="21.IkedaKet al.Fatal hepatitis B virus reactivation in a chronic myeloid" exact="leukemia" post="patient during imatinib mesylate treatmentLeukemia &amp;amp; lymphoma20064715515710.1080/1463923050023681816321842 22.KangBWet al.Chronic"/>
  <result pre="leukemia patient during imatinib mesylate treatmentLeukemia &amp;amp; lymphoma20064715515710.1080/1463923050023681816321842 22.KangBWet al.Chronic" exact="myeloid leukemia" post="patient manifesting fatal hepatitis B virus reactivation during treatment"/>
  <result pre="patient during imatinib mesylate treatmentLeukemia &amp;amp; lymphoma20064715515710.1080/1463923050023681816321842 22.KangBWet al.Chronic myeloid" exact="leukemia" post="patient manifesting fatal hepatitis B virus reactivation during treatment"/>
  <result pre="treatmentLeukemia &amp;amp; lymphoma20064715515710.1080/1463923050023681816321842 22.KangBWet al.Chronic myeloid leukemia patient manifesting fatal" exact="hepatitis" post="B virus reactivation during treatment with imatinib rescued by"/>
  <result pre="and literature reviewInternational journal of hematology20099038338710.1007/s12185-009-0386-219641858 23.AndoTet al.Reactivation of resolved" exact="infection" post="with the hepatitis B virus immune escape mutant G145R"/>
  <result pre="journal of hematology20099038338710.1007/s12185-009-0386-219641858 23.AndoTet al.Reactivation of resolved infection with the" exact="hepatitis" post="B virus immune escape mutant G145R during dasatinib treatment"/>
  <result pre="B virus immune escape mutant G145R during dasatinib treatment for" exact="chronic" post="myeloid leukemiaInternational journal of hematology201510237938210.1007/s12185-015-1788-y25842192 24.ThiaTJTanHHChuahTHChowWCLuiHFImatinib mesylate-related fatal acute"/>
  <result pre="for chronic myeloid leukemiaInternational journal of hematology201510237938210.1007/s12185-015-1788-y25842192 24.ThiaTJTanHHChuahTHChowWCLuiHFImatinib mesylate-related fatal" exact="acute" post="hepatic failure in a patient with chronic myeloid leukaemia"/>
  <result pre="24.ThiaTJTanHHChuahTHChowWCLuiHFImatinib mesylate-related fatal acute hepatic failure in a patient with" exact="chronic" post="myeloid leukaemia and chronic hepatitis B infectionSingapore medical journal200849e868918362995"/>
  <result pre="fatal acute hepatic failure in a patient with chronic myeloid" exact="leukaemia" post="and chronic hepatitis B infectionSingapore medical journal200849e868918362995 25.SoraFet al.Low"/>
  <result pre="hepatic failure in a patient with chronic myeloid leukaemia and" exact="chronic hepatitis" post="B infectionSingapore medical journal200849e868918362995 25.SoraFet al.Low risk of hepatitis"/>
  <result pre="failure in a patient with chronic myeloid leukaemia and chronic" exact="hepatitis" post="B infectionSingapore medical journal200849e868918362995 25.SoraFet al.Low risk of hepatitis"/>
  <result pre="chronic hepatitis B infectionSingapore medical journal200849e868918362995 25.SoraFet al.Low risk of" exact="hepatitis" post="B virus reactivation in patients with resolved infection and"/>
  <result pre="risk of hepatitis B virus reactivation in patients with resolved" exact="infection" post="and chronic myeloid leukemia treated with tyrosine kinase inhibitorsLeukemia"/>
  <result pre="hepatitis B virus reactivation in patients with resolved infection and" exact="chronic" post="myeloid leukemia treated with tyrosine kinase inhibitorsLeukemia &amp;amp; lymphoma20175899399510.1080/10428194.2016.121990627546591"/>
  <result pre="B virus reactivation in patients with resolved infection and chronic" exact="myeloid leukemia" post="treated with tyrosine kinase inhibitorsLeukemia &amp;amp; lymphoma20175899399510.1080/10428194.2016.121990627546591 26.Rodríguez-Tajes, S."/>
  <result pre="virus reactivation in patients with resolved infection and chronic myeloid" exact="leukemia" post="treated with tyrosine kinase inhibitorsLeukemia &amp;amp; lymphoma20175899399510.1080/10428194.2016.121990627546591 26.Rodríguez-Tajes, S."/>
  <result pre="kinase inhibitorsLeukemia &amp;amp; lymphoma20175899399510.1080/10428194.2016.121990627546591 26.Rodríguez-Tajes, S. et al. Prevalence of" exact="Hepatitis" post="B and C infection in Catalonia. Annual meeting of"/>
  <result pre="26.Rodríguez-Tajes, S. et al. Prevalence of Hepatitis B and C" exact="infection" post="in Catalonia. Annual meeting of the AEEH. (2017). 27.Salleras,"/>
  <result pre="the AEEH. (2017). 27.Salleras, L. et al. Declining prevalence of" exact="hepatitis" post="B virus infection in Catalonia (Spain) 12 years after"/>
  <result pre="(2017). 27.Salleras, L. et al. Declining prevalence of hepatitis B" exact="virus infection" post="in Catalonia (Spain) 12 years after the introduction of"/>
  <result pre="27.Salleras, L. et al. Declining prevalence of hepatitis B virus" exact="infection" post="in Catalonia (Spain) 12 years after the introduction of"/>
  <result pre="doi:S0264-410X(07)01196-6 [pii], 10.1016/j.vaccine.2007.10.02o7 (2007). 28.AASLD. Emerging Trends Conference: Reactivation of" exact="Hepatitis" post="B. (2013). 29.Newcombe, R. G. Interval estimation for the"/>
 </snippets>
</snippetsTree>
